Meningococcal meningitis in two patients with primary antibody deficiency treated with replacement intravenous immunoglobulin
- PMID: 17071803
- PMCID: PMC1860521
- DOI: 10.1136/jcp.2005.031054
Meningococcal meningitis in two patients with primary antibody deficiency treated with replacement intravenous immunoglobulin
Abstract
The current treatment of primary antibody deficiency (PAD) is the early recognition of the condition and replacement immunoglobulin combined with prompt treatment of infections and complications. The route of administration (intravenous or subcutaneous), dose and frequency of administration of immunoglobulin still vary between centres and countries. Most infections in patients with PAD are reduced but not entirely prevented by replacement immunoglobulin, with sinopulmonary infections accounting for the bulk of the remainder. Although there have been reports of meningitis in patients with PAD before replacement treatment, we describe the first two cases of bacterial meningitis (group B Neisseria meningitidis) on adequate immunoglobulin replacement and discuss the involvement of potential cofactors.
Conflict of interest statement
Competing interests: None declared.
References
-
- Cunningham‐Rundles C, Bodian C. Common variable immunodeficiency: clinical and immunologic analyses of 248 patients. Clin Immunol 19999234–48. - PubMed
-
- Spickett M A, Chapel H M. Audit of patients with primary antibody deficiency in the United Kingdom 1993–1996. Consensus document for the diagnosis and management of patients with primary antibody deficiencies, October 1995
-
- Warrell D A, Farrar J J, Crook D W M. Bacterial meningitis. In: Warrell DA, Cox TM, Benz EJ, eds. Oxford textbook of medicine. 4th edn. Oxford: Oxford University Press, 2003
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources